162 related articles for article (PubMed ID: 25763924)
1. The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.
Penn MS; Yenikomshian MA; Cummings AK; Klemes A; Damron JM; Purvis S; Beidelschies M; Birnbaum HG
J Med Econ; 2015; 18(7):483-91. PubMed ID: 25763924
[TBL] [Abstract][Full Text] [Related]
2. Predicting the impact of population level risk reduction in cardio-vascular disease and stroke on acute hospital admission rates over a 5 year period--a pilot study.
Whitfield MD; Gillett M; Holmes M; Ogden E
Public Health; 2006 Dec; 120(12):1140-8. PubMed ID: 17084425
[TBL] [Abstract][Full Text] [Related]
3. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and medicare populations: A data analysis.
Huse DM; Song X; Ozminkowski RJ; Maguire J; Williams SA; Borok GM; McDonough K
Clin Ther; 2006 Sep; 28(9):1425-42. PubMed ID: 17062315
[TBL] [Abstract][Full Text] [Related]
4. Long-term cardiovascular risk and costs for myocardial infarction survivors in a US commercially insured population.
Kern DM; Mellström C; Hunt PR; Tunceli O; Wu B; Westergaard M; Hammar N
Curr Med Res Opin; 2016; 32(4):703-11. PubMed ID: 26709864
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Kok L; Engelfriet P; Jacobs-van der Bruggen MA; Hoogenveen RT; Boshuizen HC; Verschuren MW
Eur J Cardiovasc Prev Rehabil; 2009 Jun; 16(3):371-6. PubMed ID: 19305351
[TBL] [Abstract][Full Text] [Related]
6. Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States.
Borer JS; Kansal AR; Dorman ED; Krotneva S; Zheng Y; Patel HK; Tavazzi L; Komajda M; Ford I; Böhm M; Kielhorn A
J Manag Care Spec Pharm; 2016 Sep; 22(9):1064-71. PubMed ID: 27579829
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Montouchet C; Ruff L; Balu S
J Med Econ; 2013 Jul; 16(7):907-16. PubMed ID: 23641809
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular event costs in patients with Type 2 diabetes mellitus.
Johnston SS; Sheehan JJ; Shah M; Cappell K; Princic N; Smith D; Kalsekar I
J Med Econ; 2015; 18(12):1032-40. PubMed ID: 26189723
[TBL] [Abstract][Full Text] [Related]
10. Retrospective study of total healthcare costs associated with chronic nonvalvular atrial fibrillation and the occurrence of a first transient ischemic attack, stroke or major bleed.
Boccuzzi SJ; Martin J; Stephenson J; Kreilick C; Fernandes J; Beaulieu J; Hauch O; Kim J
Curr Med Res Opin; 2009 Dec; 25(12):2853-64. PubMed ID: 19916729
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
Chiao E; Meyer K
Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic outcomes among elderly myocardial infarction survivors in the United States.
Yang E; Stokes M; Johansson S; Mellström C; Magnuson E; Cohen DJ; Hunt P
Cardiovasc Ther; 2016 Dec; 34(6):450-459. PubMed ID: 27564212
[TBL] [Abstract][Full Text] [Related]
13. Cost savings associated with an education campaign on the diagnosis and management of sleep-disordered breathing: a retrospective, claims-based US study.
Potts KJ; Butterfield DT; Sims P; Henderson M; Shames CB
Popul Health Manag; 2013 Feb; 16(1):7-13. PubMed ID: 22823227
[TBL] [Abstract][Full Text] [Related]
14. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from the Netherlands.
Boersma C; Gansevoort RT; Pechlivanoglou P; Visser ST; van Toly FF; de Jong-van den Berg LT; de Jong PE; Postma MJ;
Clin Ther; 2010 Jun; 32(6):1103-21. PubMed ID: 20637965
[TBL] [Abstract][Full Text] [Related]
15. Effect of a pharmacist-managed hypertension program on health system costs: an evaluation of the Study of Cardiovascular Risk Intervention by Pharmacists-Hypertension (SCRIP-HTN).
Houle SK; Chuck AW; McAlister FA; Tsuyuki RT
Pharmacotherapy; 2012 Jun; 32(6):527-37. PubMed ID: 22552863
[TBL] [Abstract][Full Text] [Related]
16. The estimated costs and savings of medical nutrition therapy: the Medicare population.
Sheils JF; Rubin R; Stapleton DC
J Am Diet Assoc; 1999 Apr; 99(4):428-35. PubMed ID: 10207394
[TBL] [Abstract][Full Text] [Related]
17. Bleeding as an outcome among patients with nonvalvular atrial fibrillation in a large managed care population.
Deitelzweig SB; Pinsky B; Buysman E; Lacey M; Makenbaeva D; Wiederkehr D; Graham J
Clin Ther; 2013 Oct; 35(10):1536-45.e1. PubMed ID: 24075151
[TBL] [Abstract][Full Text] [Related]
18. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
Wald NJ; Luteijn JM; Morris JK; Taylor D; Oppenheimer P
Eur J Epidemiol; 2016 Apr; 31(4):415-26. PubMed ID: 26946426
[TBL] [Abstract][Full Text] [Related]
19. Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation.
Amin A; Stokes M; Wu N; Gatt E; Makenbaeva D; Wiederkehr D; Boulanger L
J Med Econ; 2013 Oct; 16(10):1193-202. PubMed ID: 23883416
[TBL] [Abstract][Full Text] [Related]
20. Retrospective claims database analysis to determine relationship between renin-angiotensin system agents, rehospitalization, and health care costs in patients with heart failure or myocardial infarction.
Sun SX; Ye X; Lee KY; Dupclay L; Plauschinat C
Clin Ther; 2008; 30 Pt 2():2217-27. PubMed ID: 19281916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
